Oncology medications made up 24.14% of pharmacy program participants' drug spend from April 2023 to March 2024, according to Vizient's "Summer 2024 Pharmacy Market Outlook" report.
The report, released July 30, analyzed pharmacy program participants' purchase data from April 2023 to March 2024 and provides an estimate of pharmaceutical price changes for 2025.
Vizient's analysts predicted a 4.18% drug price inflation rate for oncology medication in 2025, more than the predicted 3.81% overall drug price inflation rate.
The oncology medications that saw the biggest share of spending were:
- Keytruda (pembrolizumab): 3.28%
- Darzalex Faspro (daratumumab-hyaluronidase-fihj): 1.36%
- Opdivo (nivolumab): 1.24%
- Imfinzi (durvalumab): 0.61%
- Tecentriq (atezolizumab): 0.54%
- Blincyto (blinatumomab): 0.53%
- Jakafi (ruxolitinib phosphate): 0.50%
- Perjeta (pertuzumab): 0.48%
- Adcetris (brentuximab vedotin): 0.45%
- Tagrisso (osimertinib mesylate): 0.45%
The top oncology medications with the greatest change in spend were:
- Kisqali (ribociclib): 190% increase
- Padcev (enfortumab vedotin-efjv): 69% increase
- Blincyto (blinatumomab): 56% increase
- Imfinzi (durvalumab): 38% increase
- Darzalex Faspro (daratumumab-hyaluronidase-fihj): 17% increase
- Keytruda (pembrolizumab): 13% increase